[Form 4] Incyte Genomics Inc Insider Trading Activity
Form 4 filing overview 鈥� Incyte Corp. (INCY)
Executive Vice President & Chief Medical Officer Dr. Steven H. Stein reported an internal share withholding transaction dated 07/02/2025. The Code 鈥淔鈥� event reflects 12,714 common shares automatically withheld by the issuer to cover tax obligations arising from the settlement of previously granted restricted stock units (RSUs) or earned performance shares. The withholding price was $68.17 per share.
After the transaction, Dr. Stein directly owns 112,418 common shares. This figure includes 94,907 unvested RSUs/performance shares that remain subject to future vesting conditions. No open-market purchases or sales and no derivative security activity were reported.
The filing represents a routine administrative tax-related disposition and does not signal a discretionary sale. There are no indications of broader strategic changes, earnings data, or material corporate developments within this document.
Riepilogo della presentazione del Modulo 4 鈥� Incyte Corp. (INCY)
Il Vicepresidente Esecutivo e Chief Medical Officer Dr. Steven H. Stein ha segnalato una transazione interna di ritenuta azionaria datata 07/02/2025. L鈥檈vento con codice 鈥淔鈥� indica che 12.714 azioni ordinarie sono state automaticamente trattenute dall鈥檈mittente per coprire le obbligazioni fiscali derivanti dalla liquidazione di unit脿 azionarie ristrette (RSU) precedentemente assegnate o azioni di performance maturate. Il prezzo di ritenuta 猫 stato di $68,17 per azione.
Dopo la transazione, il Dr. Stein possiede direttamente 112.418 azioni ordinarie. Questa cifra include 94.907 RSU/azioni di performance non ancora maturate che restano soggette a condizioni di maturazione future. Non sono state segnalate operazioni di acquisto o vendita sul mercato aperto n茅 attivit脿 su strumenti derivati.
La presentazione rappresenta una normale operazione amministrativa legata a imposte e non indica una vendita discrezionale. Non vi sono indicazioni di cambiamenti strategici pi霉 ampi, dati sugli utili o sviluppi societari rilevanti all鈥檌nterno di questo documento.
Resumen de la presentaci贸n del Formulario 4 鈥� Incyte Corp. (INCY)
El Vicepresidente Ejecutivo y Director M茅dico Dr. Steven H. Stein report贸 una transacci贸n interna de retenci贸n de acciones con fecha 07/02/2025. El evento con c贸digo 鈥淔鈥� refleja que 12,714 acciones comunes fueron retenidas autom谩ticamente por el emisor para cubrir obligaciones fiscales derivadas del cumplimiento de unidades restringidas de acciones (RSUs) previamente otorgadas o acciones por desempe帽o ganadas. El precio de retenci贸n fue de $68.17 por acci贸n.
Despu茅s de la transacci贸n, el Dr. Stein posee directamente 112,418 acciones comunes. Esta cifra incluye 94,907 RSUs/acciones por desempe帽o no devengadas que permanecen sujetas a condiciones futuras de adquisici贸n. No se reportaron compras o ventas en el mercado abierto ni actividad con valores derivados.
La presentaci贸n representa una disposici贸n administrativa rutinaria relacionada con impuestos y no indica una venta discrecional. No hay indicios de cambios estrat茅gicos m谩s amplios, datos de ganancias ni desarrollos corporativos materiales en este documento.
Form 4 鞝滌稖 臧滌殧 鈥� Incyte Corp. (INCY)
斓滉碃鞖挫榿毂呾瀯鞛� 瓴� 斓滉碃鞚橂毂呾瀯鞛� Dr. Steven H. Stein鞚赌 2025雲� 7鞗� 2鞚�鞛愲 雮措秬 欤检嫕 鞗愳矞歆曥垬 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 旖旊摐 鈥淔鈥� 鞚措菠韸鸽姅 鞚挫爠鞐� 攵�鞐悳 鞝滍暅 欤检嫕 雼渼(RSU) 霕愲姅 靹标臣 欤检嫕鞚� 鞝曥偘鞐� 霐半ジ 靹戈笀 鞚橂毳� 於╇嫻頃橁赴 鞙勴暣 氚滍枆鞛愱皜 鞛愲彊鞙茧 12,714 氤错喌欤�毳� 鞗愳矞歆曥垬頄堨潓鞚� 雮橅儉雰呺媹雼�. 鞗愳矞歆曥垬 臧�瓴╈澏� 欤茧嫻 $68.17鞓赌鞀惦媹雼�.
瓯半灅 頉� Dr. Stein鞚赌 歆侅爲 112,418 氤错喌欤�毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞚� 靾橃箻鞐愲姅 氙鸽灅 甓岆Μ 頇曥爼 臁瓣贝鞚� 鞝侅毄霅橂姅 94,907臧滌潣 氙疙檿鞝� RSU/靹标臣 欤检嫕鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 瓿店皽 鞁滌灔鞐愳劀鞚� 毵れ垬 霕愲姅 毵る弰, 韺岇儩靸來拡 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
鞚措矆 鞝滌稖鞚赌 靹戈笀 甏�霠� 鞚检儊鞝侅澑 甏�毽� 觳橂秳鞚� 雮橅儉雮措┌ 鞛勳潣 毵る弰毳� 鞚橂頃橃 鞎婌姷雼堧嫟. 鞚� 氍胳劀鞐愲姅 甏戨矓鞙勴暅 鞝勲灥鞝� 氤�頇�, 靾橃澋 雿办澊韯� 霕愲姅 欷戩殧頃� 旮办梾 臧滊皽鞐� 雽�頃� 歆曧泟臧� 鞐嗢姷雼堧嫟.
R茅sum茅 du d茅p么t du Formulaire 4 鈥� Incyte Corp. (INCY)
Le Vice-Pr茅sident Ex茅cutif et Directeur M茅dical Dr. Steven H. Stein a d茅clar茅 une op茅ration interne de retenue d鈥檃ctions dat茅e du 02/07/2025. L鈥櫭﹙茅nement cod茅 芦 F 禄 refl猫te la retenue automatique par l鈥櫭﹎etteur de 12 714 actions ordinaires pour couvrir les obligations fiscales li茅es au r猫glement d鈥檜nit茅s d鈥檃ctions restreintes (RSU) pr茅c茅demment attribu茅es ou d鈥檃ctions de performance acquises. Le prix de retenue 茅tait de 68,17 $ par action.
Apr猫s cette op茅ration, le Dr Stein d茅tient directement 112 418 actions ordinaires. Ce chiffre inclut 94 907 RSU/actions de performance non acquises qui restent soumises 脿 des conditions d鈥檃cquisition futures. Aucun achat ou vente sur le march茅 ouvert, ni activit茅 sur titres d茅riv茅s n鈥檃 茅t茅 signal茅.
Ce d茅p么t repr茅sente une op茅ration administrative courante li茅e 脿 la fiscalit茅 et ne signale pas une vente discr茅tionnaire. Aucun indice de changements strat茅giques majeurs, de donn茅es sur les b茅n茅fices ou de d茅veloppements importants de l鈥檈ntreprise n鈥檈st pr茅sent dans ce document.
脺bersicht der Form 4 Einreichung 鈥� Incyte Corp. (INCY)
Der Executive Vice President & Chief Medical Officer Dr. Steven H. Stein meldete eine interne Aktieneinbehaltstransaktion mit dem Datum 07.02.2025. Das Code-鈥濬鈥�-Ereignis zeigt an, dass 12.714 Stammaktien automatisch vom Emittenten einbehalten wurden, um Steuerverpflichtungen aus der Abwicklung zuvor gew盲hrter Restricted Stock Units (RSUs) oder erworbener Performance-Aktien zu erf眉llen. Der Einbehaltspreis betrug 68,17 $ pro Aktie.
Nach der Transaktion besitzt Dr. Stein direkt 112.418 Stammaktien. Diese Zahl umfasst 94.907 nicht unverfallbare RSUs/Performance-Aktien, die noch zuk眉nftigen Unverfallbarkeitsbedingungen unterliegen. Es wurden keine K盲ufe oder Verk盲ufe am offenen Markt und keine Aktivit盲ten mit derivativen Wertpapieren gemeldet.
Die Einreichung stellt eine routinem盲脽ige administrative steuerbedingte Transaktion dar und signalisiert keinen diskretion盲ren Verkauf. Es gibt keine Hinweise auf umfassendere strategische 脛nderungen, Gewinnzahlen oder wesentliche Unternehmensentwicklungen in diesem Dokument.
- Executive retains significant equity stake of 112,418 shares, reinforcing alignment with shareholder interests.
- 12,714 shares removed from float due to tax withholding slightly dilutes the executive鈥檚 direct ownership.
Insights
TL;DR 鈥� Routine tax withholding; neutral impact
The Code F transaction is purely administrative: shares were surrendered to cover taxes on vesting equity awards. Dr. Stein鈥檚 post-transaction holding of 112.4k shares (direct + unvested) maintains meaningful insider alignment. Because the shares were not sold into the open market, supply-demand dynamics are unaffected. No change to investment thesis; I classify the filing as not impactful.
TL;DR 鈥� Filing confirms equity plan compliance
The Form 4 evidences correct execution of Incyte鈥檚 equity compensation plan and Section 16 reporting obligations. Share withholding for taxes is standard practice and carries no governance red flags. Continued sizable ownership by the CMO supports shareholder alignment. No other material information surfaces, thus the filing is largely procedural.
Riepilogo della presentazione del Modulo 4 鈥� Incyte Corp. (INCY)
Il Vicepresidente Esecutivo e Chief Medical Officer Dr. Steven H. Stein ha segnalato una transazione interna di ritenuta azionaria datata 07/02/2025. L鈥檈vento con codice 鈥淔鈥� indica che 12.714 azioni ordinarie sono state automaticamente trattenute dall鈥檈mittente per coprire le obbligazioni fiscali derivanti dalla liquidazione di unit脿 azionarie ristrette (RSU) precedentemente assegnate o azioni di performance maturate. Il prezzo di ritenuta 猫 stato di $68,17 per azione.
Dopo la transazione, il Dr. Stein possiede direttamente 112.418 azioni ordinarie. Questa cifra include 94.907 RSU/azioni di performance non ancora maturate che restano soggette a condizioni di maturazione future. Non sono state segnalate operazioni di acquisto o vendita sul mercato aperto n茅 attivit脿 su strumenti derivati.
La presentazione rappresenta una normale operazione amministrativa legata a imposte e non indica una vendita discrezionale. Non vi sono indicazioni di cambiamenti strategici pi霉 ampi, dati sugli utili o sviluppi societari rilevanti all鈥檌nterno di questo documento.
Resumen de la presentaci贸n del Formulario 4 鈥� Incyte Corp. (INCY)
El Vicepresidente Ejecutivo y Director M茅dico Dr. Steven H. Stein report贸 una transacci贸n interna de retenci贸n de acciones con fecha 07/02/2025. El evento con c贸digo 鈥淔鈥� refleja que 12,714 acciones comunes fueron retenidas autom谩ticamente por el emisor para cubrir obligaciones fiscales derivadas del cumplimiento de unidades restringidas de acciones (RSUs) previamente otorgadas o acciones por desempe帽o ganadas. El precio de retenci贸n fue de $68.17 por acci贸n.
Despu茅s de la transacci贸n, el Dr. Stein posee directamente 112,418 acciones comunes. Esta cifra incluye 94,907 RSUs/acciones por desempe帽o no devengadas que permanecen sujetas a condiciones futuras de adquisici贸n. No se reportaron compras o ventas en el mercado abierto ni actividad con valores derivados.
La presentaci贸n representa una disposici贸n administrativa rutinaria relacionada con impuestos y no indica una venta discrecional. No hay indicios de cambios estrat茅gicos m谩s amplios, datos de ganancias ni desarrollos corporativos materiales en este documento.
Form 4 鞝滌稖 臧滌殧 鈥� Incyte Corp. (INCY)
斓滉碃鞖挫榿毂呾瀯鞛� 瓴� 斓滉碃鞚橂毂呾瀯鞛� Dr. Steven H. Stein鞚赌 2025雲� 7鞗� 2鞚�鞛愲 雮措秬 欤检嫕 鞗愳矞歆曥垬 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 旖旊摐 鈥淔鈥� 鞚措菠韸鸽姅 鞚挫爠鞐� 攵�鞐悳 鞝滍暅 欤检嫕 雼渼(RSU) 霕愲姅 靹标臣 欤检嫕鞚� 鞝曥偘鞐� 霐半ジ 靹戈笀 鞚橂毳� 於╇嫻頃橁赴 鞙勴暣 氚滍枆鞛愱皜 鞛愲彊鞙茧 12,714 氤错喌欤�毳� 鞗愳矞歆曥垬頄堨潓鞚� 雮橅儉雰呺媹雼�. 鞗愳矞歆曥垬 臧�瓴╈澏� 欤茧嫻 $68.17鞓赌鞀惦媹雼�.
瓯半灅 頉� Dr. Stein鞚赌 歆侅爲 112,418 氤错喌欤�毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞚� 靾橃箻鞐愲姅 氙鸽灅 甓岆Μ 頇曥爼 臁瓣贝鞚� 鞝侅毄霅橂姅 94,907臧滌潣 氙疙檿鞝� RSU/靹标臣 欤检嫕鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 瓿店皽 鞁滌灔鞐愳劀鞚� 毵れ垬 霕愲姅 毵る弰, 韺岇儩靸來拡 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
鞚措矆 鞝滌稖鞚赌 靹戈笀 甏�霠� 鞚检儊鞝侅澑 甏�毽� 觳橂秳鞚� 雮橅儉雮措┌ 鞛勳潣 毵る弰毳� 鞚橂頃橃 鞎婌姷雼堧嫟. 鞚� 氍胳劀鞐愲姅 甏戨矓鞙勴暅 鞝勲灥鞝� 氤�頇�, 靾橃澋 雿办澊韯� 霕愲姅 欷戩殧頃� 旮办梾 臧滊皽鞐� 雽�頃� 歆曧泟臧� 鞐嗢姷雼堧嫟.
R茅sum茅 du d茅p么t du Formulaire 4 鈥� Incyte Corp. (INCY)
Le Vice-Pr茅sident Ex茅cutif et Directeur M茅dical Dr. Steven H. Stein a d茅clar茅 une op茅ration interne de retenue d鈥檃ctions dat茅e du 02/07/2025. L鈥櫭﹙茅nement cod茅 芦 F 禄 refl猫te la retenue automatique par l鈥櫭﹎etteur de 12 714 actions ordinaires pour couvrir les obligations fiscales li茅es au r猫glement d鈥檜nit茅s d鈥檃ctions restreintes (RSU) pr茅c茅demment attribu茅es ou d鈥檃ctions de performance acquises. Le prix de retenue 茅tait de 68,17 $ par action.
Apr猫s cette op茅ration, le Dr Stein d茅tient directement 112 418 actions ordinaires. Ce chiffre inclut 94 907 RSU/actions de performance non acquises qui restent soumises 脿 des conditions d鈥檃cquisition futures. Aucun achat ou vente sur le march茅 ouvert, ni activit茅 sur titres d茅riv茅s n鈥檃 茅t茅 signal茅.
Ce d茅p么t repr茅sente une op茅ration administrative courante li茅e 脿 la fiscalit茅 et ne signale pas une vente discr茅tionnaire. Aucun indice de changements strat茅giques majeurs, de donn茅es sur les b茅n茅fices ou de d茅veloppements importants de l鈥檈ntreprise n鈥檈st pr茅sent dans ce document.
脺bersicht der Form 4 Einreichung 鈥� Incyte Corp. (INCY)
Der Executive Vice President & Chief Medical Officer Dr. Steven H. Stein meldete eine interne Aktieneinbehaltstransaktion mit dem Datum 07.02.2025. Das Code-鈥濬鈥�-Ereignis zeigt an, dass 12.714 Stammaktien automatisch vom Emittenten einbehalten wurden, um Steuerverpflichtungen aus der Abwicklung zuvor gew盲hrter Restricted Stock Units (RSUs) oder erworbener Performance-Aktien zu erf眉llen. Der Einbehaltspreis betrug 68,17 $ pro Aktie.
Nach der Transaktion besitzt Dr. Stein direkt 112.418 Stammaktien. Diese Zahl umfasst 94.907 nicht unverfallbare RSUs/Performance-Aktien, die noch zuk眉nftigen Unverfallbarkeitsbedingungen unterliegen. Es wurden keine K盲ufe oder Verk盲ufe am offenen Markt und keine Aktivit盲ten mit derivativen Wertpapieren gemeldet.
Die Einreichung stellt eine routinem盲脽ige administrative steuerbedingte Transaktion dar und signalisiert keinen diskretion盲ren Verkauf. Es gibt keine Hinweise auf umfassendere strategische 脛nderungen, Gewinnzahlen oder wesentliche Unternehmensentwicklungen in diesem Dokument.
FAQ
What type of transaction did INCY insider Steven H. Stein report?
How many Incyte shares does the CMO hold after the transaction?
Was there any open-market sale or purchase in this Form 4?
Does the filing affect Incyte鈥檚 share count or earnings outlook?
Why is the transaction price listed at $68.17 per share?
